Antigen-specific immunotherapy, an approach to selectively block autoimmune diabetes, generally declines in nonobese diabetic (NOD) mice as disease progresses. To define the parameters influencing the efficacy of antigenspecific immunotherapy once diabetes is established, plasmid DNA (pDNA) vaccination was used to suppress autoimmune-mediated destruction of syngeneic islet grafts in diabetic NOD recipients. pDNAs encoding a glutamic acid decarboxylase 65 (GAD65)-Ig molecule (pGAD65), interleukin (IL)-4 (pIL4), and IL-10 (pIL10) significantly delayed the onset of recurrent diabetes compared with pGAD65؉pIL10-vaccinated recipients. Despite differences in efficacy, a similar frequency of GAD65-specific CD4 ؉ T-cells secreting IL-4, IL-10, or interferon-␥ were detected in mice treated with pGAD65؉pIL4؉pIL10 and pGAD65؉pIL10. However, the frequency of FoxP3-expressing CD4
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ϩ T-cells. Reduced frequencies of ␤-cell-specific "adaptive" immunoregulatory CD4
ϩ T-cells, such as Th2 and Tr1 cells, have been reported in diabetic individuals and nonobese diabetic (NOD) mice (4 -8) . These CD4 ϩ T effectors regulate autoimmunity primarily through the bystander effects of interleukin (IL)-4 and -10 secretion. Diminished numbers and/or suppressor function of "natural" regulatory CD4 ϩ
CD25
ϩ CD62L hi T-cells (CD4 ϩ CD25 ϩ Treg) also have been documented in diabetic NOD mice and patients (9 -14) . CD4 ϩ CD25 ϩ Treg cells are characterized by a potent suppressor capacity mediated by cell-tocell contact and/or expression of transforming growth factor (TGF)-␤1 and possibly . Whereas adaptive immunoregulatory effectors are established once naïve CD4
ϩ T-cells encounter antigen in the periphery, the phenotype and suppressor function of CD4 ϩ CD25 ϩ Treg is induced in the thymus upon recognition of self-antigen and expression of the FoxP3 transcription factor (19 -22) .
In view of the functional imbalance between pathogenic type 1 and immunoregulatory ␤-cell-specific T-cells, various strategies of immunotherapy to prevent and treat type 1 diabetes have been devised to reestablish peripheral immunoregulation (23). Previous studies (24 -27) have demonstrated that administration of ␤-cell autoantigens, such as glutamic acid decarboxylase 65 (GAD65), or insulin by various means induces Th2-and Tr1-like cells and prevents the onset of diabetes in NOD mice. Antigenspecific immunotherapy also provides a possible strategy to rescue residual ␤-cell mass and/or block autoimmunemediated destruction of islet grafts in diabetic individuals. However, whether sufficient ␤-cell-specific immunoregulatory CD4
ϩ T-cells can be induced to suppress autoimmunity under overt diabetic conditions, in which the number of pathogenic effectors is high and only a limited pool of naïve ␤-cell-specific CD4 ϩ T-cells exists (28, 29) , remains largely untested.
We previously demonstrated that administration of plasmid DNA (pDNA) vaccines encoding a GAD65 immunoglobulin (Ig) chimeric molecule, IL-4, and/or IL-10 is an effective approach to suppress late preclinical type 1 diabetes in NOD mice via induction of immunoregulatory type 2 CD4
ϩ T-cells (26, 30) . In the current study, pDNA vaccination was used to define the parameters influencing the efficacy of antigen-based immunotherapy in diabetic NOD mice. Here, survival of syngeneic islet grafts implanted in diabetic recipients was used as a functional measure of suppression of ␤-cell autoimmunity. We demonstrate that suppressing ␤-cell autoimmunity in diabetic recipients is dependent on the frequency and persistence of FoxP3-expressing CD4 ϩ CD25 ϩ Treg induced/expanded following pDNA vaccination.
RESEARCH DESIGN AND METHODS
NOD/LtJ, NOD.scid, and NOD.BDC2.5 (BDC2.5) (31) mice were housed under specific pathogen-free conditions. Mice were diagnosed as diabetic when urine glucose exceeded 0.25% for three successive measurements via Diastix (Bayer Corporation, Elkhart, IN). A urine glucose level of 0.25% is equivalent to a blood glucose value of 250 mg/dl (Autokit Glucose CII assay; Wako Chemicals, Richmond, VA). Mice were maintained in an American Association of Laboratory Animal Care-accredited facility, and all procedures were approved by the University of North Carolina Institutional Animal Care and Use Committee. pDNA preparation and administration. Construction and preparation of pDNAs encoding GAD65-IgFc (pGAD), hen egg lysozyme (HEL)-IgFc (pHEL), and murine IL4 (pIL4) have been previously described (10, 30) . The pNGVL3-IL10 construct (pIL10) encoding murine IL-10 was obtained from the National Gene Vector Laboratory at the University of Michigan. Diabetic NOD female mice received a total of four intramuscular (i.m.) injections in each quadricep with 50 g of pDNA prepared in PBS on a weekly basis, in addition to daily intraperitoneal (i.p.) injections of 60 units human insulin. Islet transplantation. One week after the final pDNA vaccination, mice received syngeneic islet transplants. Pancreata from NOD.scid mice were perfused with 2 mg/ml collagenase P (Roche, Indianapolis, IN) and digested for 20 min at 37°C. Islets were purified via Ficoll gradient, handpicked, washed in PBS, and implanted under the kidney capsule. Mice were considered to be euglycemic posttransplantation after two successive negative glycosuric measurements. Graft failure was defined as glycosuric values Ͼ0.25% (250 mg/dl blood glucose) for two successive measurements. Enzyme-linked immunosorbent spot. Enzyme-linked immunosorbent spot to determine the number of spot-forming cells producing interferon (IFN) ␥, IL-4, and IL-10 was carried out as described (30) . Splenocytes were prepared from individual mice, washed, resuspended at 5 ϫ 10 6 cell/ml in HL-1 medium (BioWittaker, Wakersville, MD), and plated at 1 ϫ10 6 cells/well (200 l/well). GAD65 was added at a final concentration of 10 g/ml. The cloning and preparation of murine GAD65 previously have been described (24) . An ImmunoSpot plate reader (Cellular Technology) was used to quantitate the number of spot-forming cells per well. Flow cytometric analysis. Antibodies were purchased from BD Pharmingen and used for analysis of CD4 ϩ CD25 ϩ T-cells: fluorescein isothiocyanate-rat anti-CD3 (17A2), PerCP-rat anti-CD4 (GK1.5), phycoerythrin-rat anti-CD62L (Mel-14), and allophycocyanin-rat anti-CD25 (PC61). CD4 ϩ CD25 ϩ CD62L hi and CD4 ϩ CD25 Ϫ T-cells were sorted using a MoFlo high-speed sorter (DakoCytomation, Fort Collins, CO) for single-cell real-time PCR analysis, suppression assays, and adoptive transfer experiments. Sorted bulk populations, Ͼ98% purity, were stained with the above antibodies as described (10) . Single-cell real-time PCR. Single CD4 ϩ CD25 ϩ CD62L hi or CD4 ϩ CD25 Ϫ Tcells were sorted from the pancreatic lymph node (PLN) and renal lymph node (RLN). These cells were reverse transcribed, and real-time PCR was performed using primers and probes specific for FoxP3, TGF-␤1, IL-10, and ␤-actin as described (10) . The lower limit of detection was 10 copies for all genes tested. Each gene was detected in independent real-time PCR reactions using 5 l of a 25-l total cDNA mixture. Data are represented as RNA expression normalized to ␤-actin RNA content. The normalized mRNA level for a gene was determined by the following: (raw transcript level derived from standard curve) ϫ (␤-actin corrective ratio). The ␤-actin corrective ratio was calculated as (lowest ␤-actin level within sample set)/(␤-actin level for cell of interest).
In vitro CD4
؉ CD25 ؉ T-cell suppression assay. CD4 ϩ CD25 ϩ CD62L hi Tcells sorted from the PLN or RLN were cocultured in 96-well plates with 1 ϫ 10 5 sorted CD4 ϩ CD25 Ϫ T-cells plus 1 g/ml anti-CD3ε (145-2C11) (eBioscience, San Diego, CA) and 1 ϫ 10 5 irradiated T-cell-depleted splenocytes as described (10) . T-cells were cocultured for 72 h at 37°C and pulsed with 1 Ci/well of 3 H-thymidine for 18 h. 3 H-thymidine incorporation was measured by a scintillation counter (Beckman LS6500). Percent inhibition was determined by the following equation:
. Some studies included the addition of anti-TGF-␤1, -2, or -3 (1D11) or IgG1 isotype control antibody (R&D Systems, Minneapolis, MN) at 100 g/ml. Measurement of TGF-␤ secretion via enzyme-linked immunosorbent assay. As described, a capture enzyme-linked immunosorbent assay was used to measure levels of TGF-␤ in supernatants harvested from individual wells prepared from in vitro suppression assays (10) . Cytokine concentrations in culture supernatants were determined using standard curves of hTGF-␤ (BD Pharmingen). The lower limit of detection for TGF-␤ was 40 pg/ml.
In vivo CD4
؉ CD25 ؉ T-cell suppression assay. 1.2 ϫ 10 5 CD4 ϩ CD25
ϩ T-cells sorted from the PLN of diabetic NOD female mice vaccinated with pDNA were coinjected intravenously with 1.2 ϫ 10 6 BDC2.5 CD4 ϩ T-cells into NOD.scid recipients. Splenic BDC2.5 CD4
ϩ T-cells were isolated with anti-CD4-coated magnetic microbeads (Miltenyi Biotec) and magnetic cell sorting selection. Mice were monitored daily for diabetes as described above. Characterization of islet graft insulitis. Grafted kidneys from individual mice were flash frozen in Optimal Cutting Temperature compound (Sakura Finetechnical, Tokyo, Japan) and the entire kidney sectioned. Hematoxylin and eosin staining was performed on serial tissue sections 5 microns apart.
RESULTS
Survival of syngeneic islet grafts is enhanced in diabetic NOD recipients treated with pGAD65؉ pIL4؉pIL10. To determine whether antigen-specific immunotherapy can suppress ongoing ␤-cell autoimmunity in diabetic NOD mice, pDNAs encoding GAD65, IL-4, and/or IL-10 were administered (26) . As a functional readout for suppression of ␤-cell autoimmunity, survival of syngeneic islet grafts implanted under the kidney capsule of diabetic NOD females was used. Diabetic NOD female mice maintained on insulin received four intramuscular injections over a 4-week period of pGAD65ϩpIL4ϩpIL10 or pGAD65ϩpIL10. Control groups consisted of diabetic NOD mice left untreated or receiving pHELϩpIL4ϩpIL10. One week after the final pDNA vaccination, diabetic mice received 500 -600 syngeneic islets under the kidney capsule and recurrent diabetes monitored once euglycemia was reestablished. All recipient mice vaccinated with control pHELϩpIL4ϩpIL10 or left untreated developed recurrent diabetes at a median onset of 13 and 11 days, respectively (Fig. 1A) . Onset of recurrent diabetes was similarly detected in NOD recipients treated with pGAD65ϩpIL4 ( Fig. 1A) . In contrast, NOD recipients vaccinated with pGAD65ϩpIL4ϩpIL10 exhibited a significant delay (P Ͻ 10 Ϫ3 ) in recurrent diabetes compared with pHELϩpIL4ϩpIL10-treated and untreated recipients, with a median onset of 45 days (Fig. 1A) . Grafts implanted in pGAD65ϩpIL4ϩpIL10-treated NOD recipient mice were free of cellular infiltration at 3 weeks posttransplantation (Fig. 1B) . However, at 5 weeks posttransplantation significant infiltration of the islet grafts was detected, and upon the onset of recurrent diabetes much of the graft had been destroyed (Fig. 1B) . pGAD65ϩpIL10 vaccination also resulted in a delay in recurrent diabetes relative to pHELϩpIL4ϩpIL10-treated and untreated recipients (P Ͻ 0.02), with a median onset of 19 days. However, the duration of protection was significantly shorter compared with pGAD65ϩpIL4ϩpIL10-vaccinated mice (P Ͻ 10 Ϫ3 ; Fig. 1A ). These results demonstrate that pGAD65ϩ pIL4ϩpIL10 vaccination significantly delays recurrent diabetes by preventing infiltration of grafted islets in an antigen-dependent manner. pGAD65؉pIL4؉pIL10 and pGAD65؉pIL10 vaccination induce similar GAD65-specific type 2 CD4
؉ Tcell reactivity in diabetic NOD mice. To determine how vaccination with pGAD65ϩpIL4ϩpIL10 induced more effective islet graft protection than pGAD65ϩpIL10, the frequency of GAD65-specific IFN␥-, IL-4 -, and IL-10 -secreting CD4
ϩ T-cells in the spleen of pDNA-treated diabetic NOD mice was measured via enzyme-linked immunosorbent spot. pHELϩpIL4ϩpIL10-treated and untreated diabetic NOD mice exhibited a typical type 1 profile in response to GAD65 characterized by a high frequency of IFN␥-and no detectable IL-4 -or IL-10 -secreting CD4
ϩ T-cells (Fig. 2) . In contrast, the frequency of IFN␥-secreting GAD65-specific CD4 ϩ T-cells was reduced, and a concomitant increase in IL-4 -and IL-10 -secreting GAD65-specific CD4 ϩ T-cells was detected in pGAD65ϩpIL4ϩpIL10-vaccinated diabetic NOD mice (Fig.  2) . Interestingly, a similar frequency of IFN␥-, IL-4 -, and IL-10 -secreting GAD65-specific CD4 ϩ T-cells was detected in pGAD65ϩpIL10-treated diabetic NOD mice (Fig.  2) . Analogous results were obtained in the PLN and RLN of diabetic NOD mice vaccinated with the respective pDNA and implanted with an islet graft (data not shown). These findings demonstrate that despite differences in islet graft protection, pGAD65ϩpIL4ϩpIL10 and pGAD65ϩpIL10 treatments induce similar GAD65-specific Th2-and Tr1-like cell responses in diabetic NOD mice.
The frequency of FoxP3 and TGF-␤1 coexpressing CD4
؉
CD25
؉ CD62L hi T-cells is increased by pGAD65؉ pIL4؉pIL10 vaccination. Because the disparity in islet graft protection between pGAD65ϩpIL4ϩpIL10 and pGAD65ϩpIL10 treatment did not correlate with a significant difference in GAD65-specific CD4 ϩ T-cell reactivity, a role for "natural" CD4 ϩ CD25 ϩ Treg was examined. CD62L typically is used to differentiate between activated CD4 (32) (33) (34) . Accordingly, the number of CD62L hi T-cells residing in the RLN and PLN was measured via flow cytometry in islet graft recipients treated with the pDNAs or left untreated. An increase in CD62L hi T-cells was detected in the RLN and PLN of islet graft recipients receiving pGAD65ϩpIL4ϩpIL10 compared with pHELϩ pIL4ϩpIL10 (RLN: P ϭ 0.003; PLN: P ϭ 0.006) or no pDNA (RLN: P ϭ 0.003) ( Table 1) . A significant increase in CD62L hi T-cells also was detected in the RLN (P ϭ 0.007) and PLN (P ϭ 0.01) of pGAD65ϩpIL4ϩpIL10-versus pGAD65ϩpIL10-vaccinated recipient mice (Table 1 ). No differences in the level of surface expression of CTLA-4, glucocorticoid-induced tumor necrosis factor receptor gene, CD45RB, and CD103 were detected among CD62L hi T-cells prepared from the respective groups of mice (data not shown). These findings demonstrate that the number/ frequency of CD62L hi T-cells is increased in NOD recipient mice treated with pGAD65ϩpIL4ϩpIL10 compared with pGAD65ϩpIL10-treated recipients, which in turn have elevated CD62L
hi T-cells relative to pHELϩpIL4ϩpIL10-treated or untreated recipients.
To further define the population of RLN and PLN CD62L hi T-cells induced in islet graft recipients via pDNA vaccination, mRNA expression of FoxP3, TGF-␤, and IL-10 was quantitated. For this purpose, a real-time PCR assay was used to measure RNA expression in individual cells (10) . Single CD62L
hi T-cells were sorted from the RLN and PLN prepared from pools of three mice in each treatment group and FoxP3 expression measured in the individual T-cells. Between 10 and 22% of CD62L hi T-cells prepared from the RLN and PLN of untreated and pHELϩ pIL4ϩpIL10-vaccinated recipient mice expressed FoxP3 (Fig. 3A) . In contrast, FoxP3 expression was detected in Ͼ50% of RLN and PLN CD62L
hi T-cells in pGAD65ϩ pIL4ϩpIL10 vaccinated recipient mice (Fig. 3A) . Furthermore, the frequency of FoxP3-expressing RLN and PLN CD62L
hi T-cells sorted from pGAD65ϩpIL10-vaccinated recipients was reduced more than twofold compared with recipients treated with pGAD65ϩpIL4ϩpIL10 (Fig. 3A) . As a control, FoxP3 also was assessed in sorted CD4 Next, TGF-␤1 and IL-10 expression was assessed in sorted CD62L
hi FoxP3-expressing RLN and PLN CD4 ϩ T-cells. Seventy to 90% of FoxP3-expressing CD62L hi Tcells prepared from the RLN and PLN expressed TGF-␤1 mRNA independent of the experimental group (Fig. 3B and C). Strikingly, the average level of TGF-␤1 mRNA in RLN and PLN CD62L hi T-cells was increased in pGAD65ϩ pIL4ϩpIL10-vaccinated recipient mice relative to the other experimental groups (Fig. 3B and C) . For example, a 23-and 10-fold increase in the average level of TGF-␤1 mRNA was detected in RLN and PLN CD62L
hi T-cells of pGAD65ϩ pIL4ϩpIL10-and pGAD65ϩpIL10-vaccinated recipients, respectively ( Fig. 3B and C 
ϩ Treg induced/expanded by pGAD65ϩpIL4ϩIL10 versus pGAD65ϩpIL10 had a greater capacity to suppress ␤-cell autoimmunity. To examine this possibility, PLN CD4 ϩ CD25 ϩ T-cells were sorted from diabetic NOD female mice vaccinated with pGAD65ϩpIL4ϩIL10 or pGAD65ϩpIL10 and tested for the capacity to suppress the transfer of diabetes by BDC2.5 CD4 ϩ T-cells in NOD.scid recipients. No significant difference in the onset and frequency of diabetes was detected in NOD.scid recipients injected with CD4 ϩ
ϩ T-cells prepared from pGAD65ϩpIL10-treated donor mice plus BDC2.5 CD4 ϩ T-cells compared with BDC2.5 CD4 ϩ T-cells alone (Fig. 4A) . In contrast, onset of diabetes was significantly delayed (P Յ 0.0016) in NOD.scid mice coinjected with CD4 ϩ CD25 ϩ T-cells isolated from pGAD65ϩpIL4ϩ pIL10-vaccinated NOD mice plus BDC2.5 CD4 ϩ T-cells (Fig. 4A) .
Next, the in vitro suppressor function of RLN and PLN CD62L
hi T-cells isolated from islet graft recipients injected with pDNA 3 weeks posttransplant was measured. RLN and PLN CD62L
hi T-cells sorted from pGAD65ϩpIL10-or pHELϩpIL4ϩpIL10-vaccinated recipients inhibited CD4 ϩ
Ϫ T-cell proliferation similarly ( Fig. 4B and C) . In comparison, the suppressor activity of CD62L hi T-cells isolated from the RLN (Fig. 4B) or PLN (Fig. 4C ) of pGAD65ϩpIL4ϩpIL10 was significantly increased. This difference was most notable at the lowest number (6.25 ϫ 10
3 ) of CD62L hi T-cells tested ( Fig. 4B and C) . Earlier work demonstrated that TGF-␤1 was required to mediate suppression by CD62L
hi T-cells isolated from NOD mice (10) . To determine whether this also was the case for CD62L
hi T-cells sorted from the experimental groups, the level of TGF-␤ secretion was measured in supernatants harvested from the above suppression assays. Consistent with the in vitro suppression data, similar levels of TGF-␤ were detected in cultures containing CD62L
hi T-cells sorted from pGAD65ϩpIL10-and pHELϩ pIL4ϩpIL10-vaccinated recipients, whereas the amount of TGF-␤ was significantly increased in cultures of RLN and PLN CD62L
hi T-cells prepared from pGAD65ϩpIL4ϩpIL10 NOD recipients ( Fig. 5A and B) . Furthermore, the suppressor activity displayed by RLN and PLN CD62L
hi T-cells sorted from the three experimental groups was effectively blocked by the addition of anti-TGF-␤ but not by an isotype antibody control (Fig. 5C and D) . Together, these data demonstrate that the pool of CD62L hi T-cells induced/ expanded by pGAD65ϩpIL4ϩIL10 versus pGAD65ϩpIL10 treatment exhibit increased suppressor activity that is (at least) partially TGF-␤ dependent in vitro.
Recurrent diabetes in pGAD65؉pIL4؉pIL10-vaccinated NOD recipients corresponds with a loss of FoxP3-expressing CD4
؉ CD25 ؉ CD62L hi T-cells. Although more effective than pGAD65ϩpIL10 treatment, recurrent diabetes nevertheless developed in pGAD65ϩ pIL4ϩpIL10-vaccinated islet graft recipients. One explana- hi T-cells in RLN and PLN harvested from pGAD65ϩpIL4ϩpIL10-vaccinated recipients (Table 2) , which corresponded with a concomitant increase in the frequency of CD4 ϩ CD25 ϩ CD62L lo T-cells (data not shown). Furthermore, the frequency of FoxP3-expressing RLN and PLN CD62L
hi T-cells also decreased with time (Fig. 6A ). An approximately fourfold reduction in FoxP3-expressing CD62L hi T-cells was detected in RLN harvested at the time of recurrent diabetes onset versus 3 weeks posttransplantation (Fig.  6A) . In addition, a temporal decline in the level of TGF-␤1 RNA was detected in RLN and PLN CD62L hi T-cells ( Fig.  6B and C) , which correlated with reduced levels of TGF-␤ secretion (Fig. 6E ). An ϳ10-fold reduction in TGF-␤ was seen in cultures containing 6.25 ϫ 10 3 RLN or PLN CD62L
hi T-cells prepared 5 vs. 3 weeks posttransplantation (Fig. 6E) . Consistent with a reduced frequency of FoxP3-expressing cells and TGF-␤ production, the suppressor activity of RLN and PLN CD62L
hi T-cells also declined from 3 to 5 weeks postimplantation (Fig. 6D ). These results demonstrate that decreasing numbers of induced/ expanded FoxP3-expressing CD4 ϩ CD25 ϩ Treg correlate with the onset of recurrent diabetes in pGAD65ϩpIL4ϩ pIL10-vaccinated islet graft recipients.
DISCUSSION
Defining the "rules" of antigen-specific immunotherapy is critical for the development of rational immunotherapeutic approaches to suppress ongoing ␤-cell autoimmunity and treat diabetic patients. For this purpose, we exploited a pDNA vaccination protocol to block autoimmune-mediated destruction of syngeneic islet grafts implanted in diabetic NOD recipients. Two general conclusions can be made from this study. First, suppression of ␤-cell autoimmunity in diabetic NOD recipients was dependent on the nature and frequency of the immunoregulatory T-cells induced/expanded via pDNA vaccination. Induction of Th2-and Tr1-like cells alone appeared to be insufficient to mediate effective islet graft protection. For example, a similar frequency of GAD65-specific CD4 ϩ T-cells secreting IL-4 and IL-10 (and IFN␥) was detected (Fig. 2) despite differences in efficacy of the pGAD65ϩpIL4ϩpIL10 and pGAD65ϩpIL10 treatments (Fig. 1A) . On the other hand, there was a strong correlation between the frequency and suppressor activities of CD4 ϩ CD25 ϩ Treg elicited via the respective pDNA treatments and the onset of recurrent diabetes. CD62L
hi T-cells were increased (Table 1) , and within this pool the frequency of FoxP3-expressing cells was elevated in pGAD65ϩpIL4ϩpIL10-versus pGAD65ϩ pIL10-treated mice (Fig. 3A) . Furthermore, in vivo and in vitro suppressor activity of either CD4 ϩ CD25 ϩ or CD62L hi T-cells, respectively, was enhanced in pGAD65ϩIL4ϩ pIL10-vaccinated mice compared with the pGAD65ϩpIL10 and/or pHELϩpIL4ϩpIL10 treatment groups (Fig. 4) . In addition to frequency, a qualitative difference within the pool of CD62L hi T-cells was detected depending on the pDNA vaccination protocol. For instance, Ͼ10-fold increase in TGF-␤1 mRNA expression (Fig. 3B and C) coupled with elevated levels of TGF-␤ secretion (Fig. 5) were detected for RLN and PLN CD62L
hi T-cells prepared from pGAD65ϩpIL4ϩpIL10-versus pGAD65ϩpIL10-and pHELϩIL4ϩpIL10-vaccinated diabetic recipient mice. Consistent with previous work by our group and others (10, 35, 36) , the in vitro suppressor activity of sorted CD62L hi T-cells was associated with TGF-␤ secretion (Fig.  5) , although cell-to-cell contact also contributes to in vitro suppression (S.M.P., R.T., unpublished results). The relative contribution of TGF-␤ in CD62L
hi T-cell-mediated suppression in vivo, however, is not clear. Furthermore, in vitro suppressor activity was only detected for CD62L 
CD25
ϩ Treg induced in diabetic NOD mice by anti-CD3 Ab treatment, although expression of FoxP3 was not directly examined. Others (38) suggest that contact of CD4 ϩ CD25 ϩ Treg with conventional CD4
ϩ T-cells can induce an immunoregulatory phenotype characterized by the secretion of antiinflammatory cytokines. Collectively, these findings demonstrate that effective suppression of ongoing ␤-cell autoimmunity in diabetic NOD recipients is dependent on the frequency of FoxP3-expressing CD62L
hi T-cells induced and/or expanded via pDNA vaccination.
The second general conclusion made in this study is that duration of the suppressive effect on ␤-cell autoimmunity in diabetic recipients is dependent on the persistence of CD4 ϩ CD25 ϩ Treg. The onset of recurrent diabetes in islet graft recipients vaccinated with pGAD65ϩpIL4ϩpIL10 corresponded with a temporal decline in the frequency of CD62L hi T-cells (Table 2 ) and a concomitant increase in pathogenic T-cells in the RLN and PLN. Furthermore, there was a progressive decline in the frequency of FoxP3-expressing cells within the pool of CD62L hi T-cells and the in vitro suppressor activity and levels of TGF-␤ mRNA expression and secretion by sorted RLN and PLN CD62L hi T-cells (Fig. 6) . The diminishing frequency of CD62L hi T-cells also was reflected by the progression of islet graft insulitis. At 3 weeks postimplantation, when the frequency of FoxP3-expressing CD62L hi T-cells was high, islet transplants were free of insulitis (Fig. 2) , indicating that protection was mediated by suppression of graft infiltration. However, infiltrates were readily detected as the frequency of CD4 ϩ CD25 ϩ Treg was reduced (Fig. 1B) . Studies have demonstrated time-dependent defects in the frequency and/or function of subsets of immunoregulatory CD4 ϩ T effectors in NOD mice (6 -9,11-14) . Zaghouani et al. (11) reported a temporal decrease in TGF-␤ expression by splenic CD4 ϩ CD25 ϩ Treg induced in 8-week-old nondiabetic NOD mice injected with GAD-Ig protein. Therefore, properties intrinsic to CD4 ϩ CD25 ϩ Treg and/or the extracellular environment found in NOD female mice may promote the decline of FoxP3-expressing CD62L
hi T-cells detected in pDNA vaccinated recipients. Initial attempts to maintain the pool of CD4 ϩ CD25 ϩ Treg with subsequent injections of pGAD65ϩpIL4ϩpIL10 or pIL4ϩpIL10 exacerbated the onset of recurrent diabetes (S.M.P., R.T., unpublished results), suggesting that the dynamics of the in vivo milieu that promote an immunoregulatory versus pathogenic response are highly complex. Because similar defects appear to exist in type 1 diabetic patients (14) , establishing conditions to maintain sufficient CD4 ϩ
ϩ Treg numbers and function may prove to be a key parameter for long-term suppression of ␤-cell autoimmunity in the clinic.
Importantly, islet graft protection was found to be GAD65 dependent because treatment with pHELϩpIL4ϩ pIL10 (Fig. 1 ) or pHELϩpIL10 (data not shown) failed to delay recurrent diabetes or mediate an increase in the frequency of CD4 ϩ CD25 ϩ Treg. However, whether the increased FoxP3 ϩ CD62L hi T-cells are indeed GAD65-specific still needs to be elucidated. Because thymic expression of GAD65 is detected (39) , it is plausible that GAD65-specific CD4 ϩ CD25 ϩ Treg are selected in the thymus and subsequently expanded in the periphery following pGAD65ϩpIL4ϩpIL10 vaccination. Another mutually nonexclusive scenario is that induction of GAD65-specific Th2-and Tr1-like effectors establish an extracellular milieu that in the context of exogenous IL-4 and IL-10 preferentially promotes induction/expansion of CD4 ϩ
ϩ Treg specific for other ␤-cell or islet antigens. In summary, we demonstrate that under overt diabetes conditions, antigen-specific immunotherapy can be used to establish ␤-cell-specific type 2 immunoregulatory CD4 ϩ T-cells and induce/expand FoxP3-expressing CD4 ϩ CD25 ϩ Treg. Furthermore, the degree of suppression of ongoing ␤-cell autoimmunity is dependent on the frequency and persistence of CD4 ϩ CD25 ϩ Treg. How to achieve longterm maintenance of immunoregulatory effectors needs further investigation. Accordingly, combining antigen-dependent and -independent immunotherapy strategies may prove effective in enhancing and extending suppression of ongoing ␤-cell autoimmunity in diabetic individuals (40, 41) .
